DEC 15
Signed Exclusive Licence Agreement to Commercialise Fortacin™ in the Israeli and Balkan regions
OCT 07
Deep Longevity Launches Longevity Medicine Course for Physicians with Industry Experts
AUG 30
Announces 2021 Interim Results, Significant Milestones Achieved on the Commercialisation of Fortacin™ and Business Expansion
AUG 06
Endurance Longevity Announces Positive Profit Alert for Interim Results 2021 and Other Exciting Business Updates - Fortacin To Undertake Phase III Clinical Trials in the United States, Disposal of Listed Securities of VXR Shares for A$5 million Net Proceeds
JUL 28
Fortacin Receives Extremely Encouraging Assessment in US Market Research Analysis
JUL 15
Fortacin Receives Strong Positive Results for US Phase II PRO Validation Study
JUL 14
Deep Longevity Launches Psychological Aging Clocks and Announces Scientific Advisory Board
JUN 24
Endurance RP Limited: A New Name, A New Perspective - Eye on China’s fertility and longevity market
MAY 20
Regent Pacific’s Deep Longevity announces partnership with LifeHub and LifeClinic in Hong Kong
MAY 11
Regent Pacific’s Unrealised Gain in Venturex Resources Limited Increased to US$10.74 million
APR 01
Regent Pacific Receives HK$24 million After Clinical Trial Approval For Fortacin™ Has Been Obtained
MAR 30
Regent Pacific Announces 2020 Annual Results, Significant Milestones Achieved on the Commercialisation of Fortacin™ and Business Expansion
FEB 09
Regent Pacific’s Strategic Partner Obtains Clinical Trial Approval for Fortacin™
JAN 18
Regent Pacific Announces the Successful Launch of Fortacin™ in Hong Kong, Upcoming Launches in Taiwan and Macau and Related Business Updates
JAN 11
Regent Pacific Announces Key Research Findings on Fortacin™ – Encouraging Step Towards the Commercialization of Fortacin™ in the US
JAN 04
Regent Pacific Announces Key Progresses on Fortacin™ / Senstend™ – Solution to Premature Ejaculation